Skip to Main Content

Paper Details

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Clin Cancer Res
140
2015
AR, Abiraterone, CHD1, CRPC, CYP17A1, PTEN, T878A, T878A mutation, T878A-mutant AR, abiraterone, androgen, castration-resistant prostate cancer, dutasteride, flutamide, ketoconazole, leuprolide, metastatic tumor, mutant ARs, mutant androgen receptors, patient, patients, progesterone, tumor, tumor cells, tumors, wild-type AR
Author NameAffiliation
Adam G SowalskyBeth Israel Deaconess Medical Center, Harvard Medical School
Shuai GaoBeth Israel Deaconess Medical Center, Harvard Medical School
Changmeng CaiBeth Israel Deaconess Medical Center, Harvard Medical School
Massimo LodaDana-Farber Cancer Institute, Harvard Medical School
Lawrence D TrueUniversity of Washington
Huihui YeBeth Israel Deaconess Medical Center, Harvard Medical School
Rosina T LisDana-Farber Cancer Institute, Harvard Medical School
Philip W KantoffDana-Farber Cancer Institute, Harvard Medical School
Philip W KantoffDana-Farber Cancer Institute, Harvard Medical School
Bruce MontgomeryUniversity of Washington
Peter S NelsonUniversity of Washington, Washington. Fred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington, Washington. Fred Hutchinson Cancer Research Center
Steven P BalkBeth Israel Deaconess Medical Center, Harvard Medical School
Mary-Ellen TaplinDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 14

Datasets

Release 1.2